Elite Journal of Haematology. Volume 2 Issue 6(2024), Pp. 46-59
https://epjournals.com/journals/EJH

Addressing Anemia and Hemorrhage in Pregnancy: Blood Transfusion Strategies for Improved Maternal Health

*Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda.
[2]School of Nursing Science, Kampala International University, Ishaka, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda.

Abstract

Anemia and hemorrhage during pregnancy are major contributors to maternal morbidity and mortality worldwide, necessitating effective management strategies to enhance maternal health outcomes. Anemia, predominantly due to iron deficiency, can lead to severe complications such as preterm delivery and low birth weight if not adequately addressed. Routine screening and early intervention with iron supplementation are essential, with blood transfusions reserved for severe or unresponsive cases. Postpartum hemorrhage (PPH), defined by significant blood loss following delivery, remains a leading cause of maternal death. Prompt management, including uterotonic drugs, mechanical methods, and surgical interventions, is crucial, with blood transfusions playing a vital role in stabilizing patients experiencing substantial hemorrhage. Blood transfusion strategies in obstetric care focus on optimizing patient outcomes through tailored approaches. Patient Blood Management (PBM) involves minimizing blood loss, optimizing red blood cell mass, and enhancing anemia tolerance. Transfusion decisions are guided by clinical assessments and hemoglobin levels, with a general threshold for transfusion in obstetric patients set at a hemoglobin level of <7 g/dL. Component therapy, which involves the targeted use of specific blood products, ensures patients receive the most effective treatment. Massive Transfusion Protocols (MTPs) are critical in managing severe hemorrhages, providing rapid and coordinated delivery of blood products to stabilize the patient. Despite the benefits, blood transfusion carries inherent risks, including transfusion reactions and infections, and the challenge of ensuring blood product safety and availability, especially in low-resource settings. Innovations such as tranexamic acid, cell salvage techniques, and synthetic blood products offer promising advancements in the field. The adoption of comprehensive blood transfusion strategies, adherence to evidence-based

Citation: Obeagu EI, Obeagu GU. Addressing Anemia and Hemorrhage in Pregnancy: Blood Transfusion Strategies for Improved Maternal Health. *Elite Journal of Haematology, 2024; 2(6):* 46-59

guidelines, and continuous research and innovation are essential to address the challenges and improve maternal health outcomes globally.

Keywords*: Anemia, Hemorrhage, Pregnancy, Blood Transfusion, Maternal Health, Postpartum Hemorrhage*

Introduction

Anemia and hemorrhage are among the most common and severe complications encountered during pregnancy, significantly impacting maternal morbidity and mortality. These conditions require urgent and effective management to safeguard maternal health, and blood transfusion plays a pivotal role in their treatment. Anemia in pregnancy, particularly iron-deficiency anemia, can lead to adverse outcomes such as preterm delivery and low birth weight. Meanwhile, hemorrhage, especially postpartum hemorrhage (PPH), remains one of the leading causes of maternal death globally.[1-11] The World Health Organization (WHO) estimates that approximately 40% of pregnant women globally are anemic, with iron deficiency being the most common cause. Anemia can lead to a range of complications, including maternal fatigue, increased susceptibility to infections, and severe cases, cardiac failure. The condition also poses significant risks to the fetus, including intrauterine growth restriction, preterm birth, and low birth weight, which can have long-term health implications.[12-14] Early diagnosis and management of anemia are crucial to preventing these adverse outcomes. Routine screening for hemoglobin levels is recommended as part of prenatal care. When anemia is detected, iron supplementation is the primary treatment modality. Oral iron supplements are commonly prescribed, but intravenous iron may be necessary for severe cases or when oral supplementation is ineffective or poorly tolerated. Blood transfusions are considered for pregnant women with severe anemia (hemoglobin levels below 7 g/dL) or those who exhibit symptoms unresponsive to other treatments. The goal is to rapidly restore hemoglobin levels and improve oxygen delivery to vital organs.[15-21]

Hemorrhage in pregnancy, particularly postpartum hemorrhage (PPH), is a major concern and a leading cause of maternal mortality. PPH is defined as the loss of more than 500 mL of blood after vaginal delivery or more than 1000 mL after a cesarean section. The primary cause of PPH is uterine atony, where the uterus fails to contract adequately after delivery. Other causes include retained placental tissue, lacerations, and coagulopathies. Timely recognition and management of PPH are essential to prevent severe morbidity and mortality.[22-26] The management of hemorrhage involves a multi-faceted approach, starting with the administration of uterotonic agents such as oxytocin to promote uterine contractions. Mechanical methods like balloon tamponade may also be employed to control bleeding. In cases where these measures are insufficient, surgical interventions such as uterine artery ligation or hysterectomy may be necessary. Blood transfusions are a critical component of PPH management, providing the necessary support to stabilize the patient by replacing lost blood volume and improving hemodynamic status.[27-31] Blood transfusion

strategies in obstetric care are designed to optimize outcomes and minimize risks.[32] One such strategy is Patient Blood Management (PBM), which focuses on minimizing blood loss, optimizing red blood cell mass, and enhancing the patient's tolerance to anemia. PBM is a multidisciplinary approach that involves careful planning and coordination among healthcare providers. It includes measures such as preoperative optimization of hemoglobin levels, the use of minimally invasive surgical techniques, and the judicious use of blood products.[33-37]

Decisions regarding blood transfusion in obstetric patients are guided by clinical assessments and specific hemoglobin thresholds.[38] Generally, transfusion is considered when hemoglobin levels fall below 7 g/dL, but this threshold may vary based on the patient's clinical condition and comorbidities. The aim is to ensure that transfusion is provided only when necessary and in the most effective manner. Component therapy, which involves the use of specific blood products like red blood cells, plasma, and platelets, tailored to the patient's needs, is also a key aspect of modern transfusion practice. Massive Transfusion Protocols (MTPs) are crucial in managing severe hemorrhages. These protocols are activated in situations where rapid and large-volume transfusions are required. MTPs ensure the coordinated and timely delivery of blood products, reducing the risk of coagulopathy and other complications associated with massive blood loss. The use of MTPs has been shown to improve outcomes in patients experiencing significant hemorrhage, including those with obstetric complications.[39-43] Despite the benefits, blood transfusion carries risks such as transfusion reactions, infections, and alloimmunization. Ensuring the safety and availability of blood products is a significant challenge, particularly in low-resource settings. Innovations in the field, such as the use of tranexamic acid to reduce bleeding, cell salvage techniques that allow for the recycling of the patient's own blood, and the development of synthetic blood products, hold promise for enhancing the safety and efficacy of transfusions.[44-48]

Anemia in Pregnancy

Anemia in pregnancy is a prevalent and significant health issue, particularly in low- and middle-income countries.[49] It is characterized by a deficiency in the number or quality of red blood cells or hemoglobin, impairing the blood's ability to transport oxygen. The World Health Organization (WHO) estimates that around 40% of pregnant women globally suffer from anemia, with iron deficiency being the primary cause. This condition poses serious risks to both maternal and fetal health, necessitating early diagnosis and effective management. The primary cause of anemia in pregnancy is iron deficiency, which accounts for more than half of all cases. Iron requirements increase significantly during pregnancy due to the expansion of the maternal blood volume and the growing needs of the fetus and placenta. Other causes include folate deficiency, vitamin B12 deficiency, and chronic diseases such as malaria and HIV/AIDS. Risk factors for developing anemia during pregnancy include poor nutritional status, multiple pregnancies, closely spaced

pregnancies, and pre-existing health conditions.[50-54] Anemia in pregnancy can range from mild to severe and may be asymptomatic in its early stages. Common symptoms include fatigue, weakness, dizziness, shortness of breath, and pallor. Severe anemia can lead to more serious complications such as heart failure, preterm delivery, and low birth weight. Diagnosis is typically made through routine blood tests that measure hemoglobin and hematocrit levels. Additional tests, such as serum ferritin and serum iron, may be performed to determine the underlying cause.[55-58] Effective management of anemia in pregnancy involves addressing the underlying cause and replenishing deficient nutrients.[59] For iron-deficiency anemia, oral iron supplements are the first line of treatment. These are usually well-tolerated but may cause gastrointestinal side effects such as constipation or nausea. In cases where oral iron is not effective or tolerated, intravenous iron therapy may be administered. Folic acid supplementation is also recommended, especially in areas where folate deficiency is common.

Blood Transfusion in Severe Anemia

Blood transfusion is considered for pregnant women with severe anemia (hemoglobin levels below 7 g/dL) or those with symptomatic anemia unresponsive to other treatments.[60] The goal of transfusion is to quickly restore hemoglobin levels, improve oxygen delivery, and stabilize the patient's condition. However, transfusions are not without risks, including transfusion reactions and transmission of infections. Therefore, the decision to transfuse must be carefully weighed against the potential benefits and risks. Preventing anemia in pregnancy involves several strategies, including improving dietary intake of iron and other essential nutrients, promoting iron and folic acid supplementation, and controlling infections that contribute to anemia.[61] Public health measures such as fortifying staple foods with iron and folic acid, deworming programs, and malaria prevention can also play a crucial role. Education and counseling on nutrition and prenatal care are essential components of prevention efforts.[62-63] Efforts to combat anemia in pregnancy are ongoing at both global and regional levels. The WHO has set targets to reduce the prevalence of anemia among women of reproductive age by 50% by 2025.[64] National health programs in many countries are focusing on improving maternal nutrition, enhancing access to prenatal care, and ensuring the availability of iron and folic acid supplements. Collaboration between governments, non-governmental organizations, and international agencies is crucial for achieving these goals.

Diagnosis and Management

Diagnosis

The diagnosis of anemia in pregnancy involves a systematic approach that includes clinical evaluation and laboratory testing. Early detection through routine prenatal screening is essential for effective management and preventing complications. Symptoms of anemia in pregnancy can be nonspecific and may include fatigue, weakness, dizziness, shortness of breath, and pallor.

Severe cases can present with tachycardia, hypotension, and heart failure.[65] A thorough medical history and physical examination are crucial. This includes dietary habits, history of gastrointestinal disorders, menstrual history, previous pregnancies, and any chronic illnesses.

1. **Laboratory Testing**:
    - **Complete Blood Count (CBC)**: The primary test for diagnosing anemia. It measures hemoglobin (Hb), hematocrit (Hct), and red blood cell (RBC) indices (mean corpuscular volume, mean corpuscular hemoglobin).
    - **Serum Ferritin**: Assesses iron stores in the body. Low levels are indicative of iron deficiency anemia.
    - **Serum Iron and Total Iron-Binding Capacity (TIBC)**: Helps differentiate between iron deficiency anemia and anemia of chronic disease.
    - **Peripheral Blood Smear**: Provides information on the morphology of RBCs, which can help identify the type of anemia.
    - **Reticulocyte Count**: Indicates bone marrow response and RBC production.
    - **Additional Tests**: Depending on the suspected cause, tests for vitamin B12, folate levels, and specific tests for hemolytic anemias or chronic diseases might be necessary.

Management

Effective management of anemia in pregnancy focuses on treating the underlying cause, replenishing deficient nutrients, and monitoring maternal and fetal well-being.

Oral iron supplements are the first-line treatment for iron deficiency anemia.[66] Ferrous sulfate is commonly used, but other formulations like ferrous gluconate or ferrous fumarate may be prescribed based on tolerance. Typically, 60-120 mg of elemental iron daily. Side effects such as gastrointestinal discomfort can be mitigated by taking the supplements with food or using slow-release formulations. Indicated for women who cannot tolerate oral iron, have severe anemia, or need a rapid increase in iron stores. Preparations include iron sucrose, ferric carboxymaltose, and iron dextran. Recommended for all pregnant women, especially those with folate deficiency. The standard dose is 400-800 micrograms daily. For women with confirmed vitamin B12 deficiency, intramuscular injections or high-dose oral supplements are used.[67-69] Indicated for severe anemia (Hb <7 g/dL) or symptomatic anemia not responding to oral or intravenous iron.[70] The goal is to rapidly restore hemoglobin levels, improve oxygen delivery, and stabilize the patient. Risks of transfusion include allergic reactions, febrile non-hemolytic transfusion reactions, and transfusion-transmitted infections. Therefore, transfusion decisions should be based on a thorough risk-benefit analysis. Regular follow-up appointments to monitor hemoglobin levels, iron stores, and overall health.

Citation: Obeagu EI, Obeagu GU. Addressing Anemia and Hemorrhage in Pregnancy: Blood Transfusion Strategies for Improved Maternal Health. *Elite Journal of Haematology, 2024; 2(6):* 46-59

Hemorrhage in Pregnancy

Hemorrhage during pregnancy, particularly postpartum hemorrhage (PPH), is one of the leading causes of maternal mortality and morbidity globally.[71] It requires prompt recognition and effective management to ensure the safety of both the mother and the baby. This section explores the types, causes, diagnosis, and management strategies of hemorrhage in pregnancy, with a focus on the critical role of blood transfusion.

Types and Causes

1. **Antepartum Hemorrhage**:

Occurs before the onset of labor and is typically due to conditions such as placenta previa, where the placenta partially or wholly covers the cervix, or placental abruption, where the placenta detaches from the uterus prematurely. Other causes include uterine rupture, vasa previa, and cervical or vaginal lesions.

2. **Postpartum Hemorrhage (PPH)**:

Defined as the loss of more than 500 mL of blood after vaginal delivery or more than 1000 mL after cesarean section. Primary PPH occurs within the first 24 hours after delivery and is often due to uterine atony (failure of the uterus to contract), retained placental tissue, lacerations of the genital tract, or coagulopathies. Secondary PPH occurs from 24 hours to 12 weeks postpartum and can result from retained products of conception, infection, or subinvolution of the placental site.

Preventive Measures

1. **Active Management of the Third Stage of Labor (AMTSL)**
    - **Routine Use of Uterotonics**: Administration of oxytocin immediately after delivery of the baby.
    - **Controlled Cord Traction**: Gentle pulling of the umbilical cord while supporting the uterus to deliver the placenta.
    - **Uterine Massage**: Regular massaging of the uterus after delivery to promote contraction and prevent atony.
2. **Risk Assessment and Planning**
    - **Identify High-Risk Women**: Women with previous PPH, multiple gestations, or known placental abnormalities.
    - **Individualized Management Plans**: Develop and implement tailored management plans for women at high risk of hemorrhage, including early intervention strategies and preparation for potential complications.

Citation: Obeagu EI, Obeagu GU. Addressing Anemia and Hemorrhage in Pregnancy: Blood Transfusion Strategies for Improved Maternal Health. *Elite Journal of Haematology, 2024; 2(6):* 46-59

Blood Transfusion Strategies

Blood transfusion is a critical intervention for managing severe anemia and hemorrhage in pregnancy.[72-73] Effective transfusion strategies are essential to optimize maternal health outcomes, minimize risks, and ensure the availability of safe blood products. This section outlines key strategies for blood transfusion in obstetric care, emphasizing the importance of a multidisciplinary approach, the use of massive transfusion protocols, and patient blood management principles.

Multidisciplinary Approach

1. **Team Coordination**:
    - **Obstetricians, Anesthesiologists, and Hematologists**: Close collaboration among these specialists ensures comprehensive care and effective management of hemorrhage and severe anemia.
    - **Nurses and Midwives**: They play a crucial role in early detection, continuous monitoring, and implementing transfusion protocols.
    - **Blood Bank Services**: Timely availability of blood products and efficient communication with the clinical team are vital.
2. **Training and Education**:

Regular training programs for healthcare providers on the latest guidelines and techniques in managing obstetric hemorrhage and anemia. Simulation drills to prepare the team for emergency scenarios and improve response times and coordination.

Conclusion

Addressing anemia and hemorrhage in pregnancy is critical for improving maternal health outcomes and reducing maternal mortality. These conditions present significant challenges, particularly in low-resource settings, where healthcare infrastructure, access to safe blood products, and timely diagnosis and treatment may be inadequate. The comprehensive management of anemia and hemorrhage involves a multifaceted approach that includes effective blood transfusion strategies, patient blood management, and adherence to massive transfusion protocols. Key strategies for blood transfusion in pregnancy focus on a multidisciplinary approach, ensuring collaboration among obstetricians, anesthesiologists, hematologists, nurses, and blood bank services. Training and education for healthcare providers are essential for effective response and management. Patient blood management principles, including preoperative optimization, minimizing blood loss, and enhancing tolerance of anemia, play a vital role in improving patient

Citation: Obeagu EI, Obeagu GU. Addressing Anemia and Hemorrhage in Pregnancy: Blood Transfusion Strategies for Improved Maternal Health. *Elite Journal of Haematology, 2024; 2(6):* 46-59

outcomes. Massive transfusion protocols ensure rapid and coordinated delivery of blood products during life-threatening hemorrhages.

Challenges such as resource limitations, delayed diagnosis and treatment, risks associated with transfusion, coagulation disorders, and high incidence of anemia due to nutritional deficiencies and chronic diseases complicate the management of these conditions. However, innovations in portable diagnostics, advanced blood products, improved iron supplementation, new uterotonic agents, hemostatic technologies, and educational and community-based interventions are making significant strides in overcoming these challenges. Point-of-care testing devices, smartphone applications, telemedicine, and innovative blood transfusion techniques are enhancing the ability to diagnose and manage anemia and hemorrhage effectively. Community health worker programs and educational initiatives are crucial for improving antenatal care and awareness. Furthermore, advancements in genetic screening and personalized medicine offer promising avenues for tailored interventions. Continued investment in research, technology, and healthcare infrastructure is essential to further improve maternal health outcomes. By integrating innovative solutions with evidence-based practices and addressing the systemic challenges in healthcare delivery, it is possible to significantly reduce the incidence and impact of anemia and hemorrhage in pregnancy, ensuring safer pregnancies and healthier outcomes for mothers and their babies worldwide.

References

1. Smith C, Teng F, Branch E, Chu S, Joseph KS. Maternal and perinatal morbidity and mortality associated with anemia in pregnancy. Obstetrics & Gynecology. 2019;134(6):1234-1244.
2. Shi H, Chen L, Wang Y, Sun M, Guo Y, Ma S, Wang X, Jiang H, Wang X, Lu J, Ge L. Severity of anemia during pregnancy and adverse maternal and fetal outcomes. JAMA network open. 2022;5(2):e2147046-.
3. Harrison RK, Lauhon SR, Colvin ZA, McIntosh JJ. Maternal anemia and severe maternal morbidity in a US cohort. American journal of obstetrics & gynecology MFM. 2021;3(5):100395.
4. Beckert RH, Baer RJ, Anderson JG, Jelliffe-Pawlowski LL, Rogers EE. Maternal anemia and pregnancy outcomes: a population-based study. Journal of Perinatology. 2019;39(7):911-919.
5. Daru J, Zamora J, Fernández-Félix BM, Vogel J, Oladapo OT, Morisaki N, Tunçalp Ö, Torloni MR, Mittal S, Jayaratne K, Lumbiganon P. Risk of maternal mortality in women with severe anaemia during pregnancy and post partum: a multilevel analysis. The Lancet Global Health. 2018;6(5):e548-554.
6. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC, Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria, J Res Med Dent Sci, 2021, 9 (4):145-148

Citation: Obeagu EI, Obeagu GU. Addressing Anemia and Hemorrhage in Pregnancy: Blood Transfusion Strategies for Improved Maternal Health. *Elite Journal of Haematology, 2024; 2(6):* 46-59

7. Obeagu EI, Agreen FC. Anaemia among pregnant women: A review of African pregnant teenagers. J Pub Health Nutri. 2023; 6 (1). 2023;138. links/63da799664fc860638054562/Anaemia-among-pregnant-women-A-review-of-African-pregnant-teenagers.pdf.
8. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-8. links/5710fae108ae846f4ef05afb/ERYTHROPOIETIN-IN-THE-ANAEMIAS-OF-PREGNANCY-A-REVIEW.pdf.
9. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC. Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria. J Res Med Dent Sci. 2021;9(4):145-8. links/608a6728a6fdccaebdf52d94/Assessment-of-Haematological-Changes-in-Pregnant-Women-of-Ido-Ondo.pdf.
10. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 ;6(2):10-3. http://irmhs.com/index.php/irmhs/article/view/111.
11. Georgieff MK. Iron deficiency in pregnancy. American journal of obstetrics and gynecology. 2020;223(4):516-524.
12. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. Evaluation of Protein C, Protein S and Fibrinogen of Pregnant Women with Malaria in Owerri Metropolis. Madonna University journal of Medicine and Health Sciences. 2022;2(2):1-9.
13. Obeagu EI, Ikpenwa JN, Chukwueze CM, Obeagu GU. Evaluation of protein C, protein S and fibrinogen of pregnant women in Owerri Metropolis. Madonna University Journal of Medicine and Health Sciences. 2022;2(1):292-8. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/57.
14. Obeagu EI, Obeagu GU, Adepoju OJ. Evaluation of haematological parameters of pregnant women based on age groups in Olorunsogo road area of Ido, Ondo state. J. Bio. Innov11 (3). 2022:936-941.
15. Cantor AG, Bougatsos C, Dana T, Blazina I, McDonagh M. Routine iron supplementation and screening for iron deficiency anemia in pregnancy: a systematic review for the US Preventive Services Task Force. Annals of internal medicine. 2015;162(8):566-576.
16. Siu AL, US Preventive Services Task Force*. Screening for iron deficiency anemia and iron supplementation in pregnant women to improve maternal health and birth outcomes: US Preventive Services Task Force recommendation statement. Annals of Internal Medicine. 2015;163(7):529-536.
17. Obeagu EI. An update on utilization of antenatal care among pregnant Women in Nigeria. Int. J. Curr. Res. Chem. Pharm. Sci. 2022;9(9): 21-6.DOI: 10.22192/ijcrcps.2022.09.09.003
18. Okoroiwu IL, Obeagu EI, Obeagu GU. Determination of clot retraction in preganant women attending antenatal clinic in federal medical centre Owerri, Nigeria. Madonna

University Journal of Medicine and Health Sciences. 2022;2(2):91-97. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/67.

19. Obeagu EI, Hassan AO, Adepoju OJ, Obeagu GU, Okafor CJ. Evaluation of Changes in Haematological Parameters of Pregnant Women Based on Gestational Age at Olorunsogo Road Area of Ido, Ondo State. Nigeria. Journal of Research in Medical and Dental Science. 2021;9(12):462-.links/61b1e32f0c4bfb675178bfa7/Evaluation-of-Changes-in-Haematological-Parameters-of-Pregnant-Women-Based-on-Gestational-Age-at-Olorunsogo-Road-Area-of-Ido-Ondo-State-Nigeria.pdf.
20. Anyiam AF, Obeagu EI, Obi E, Omosigho PO, Irondi EA, Arinze-Anyiam OC, Asiyah MK. ABO blood groups and gestational diabetes among pregnant women attending University of Ilorin Teaching Hospital, Kwara State, Nigeria. International Journal of Research and Reports in Hematology. 2022 Jun 21;5(2):113-121.
21. Obeagu EI. Gestational Thrombocytopaenia. J Gynecol Women's Health. 2023;25(3):556163. links/64b01aa88de7ed28ba95fccb/Gestational-Thrombocytopaenia.pdf.
22. Liu CN, Yu FB, Xu YZ, Li JS, Guan ZH, Sun MN, Liu CA, He F, Chen DJ. Prevalence and risk factors of severe postpartum hemorrhage: a retrospective cohort study. BMC pregnancy and childbirth. 2021;21(1):332.
23. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-9.
24. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU. Obsterics characteristics that effect the newborn outcomes. Int. J. Adv. Res. Biol. Sci. 2023;10(3): 134-43.DOI: 10.22192/ijarbs.2023.10.03.016
25. Obeagu EI, Ogunnaya FU. PREGNANCYINDUCED HAEMATOLOGICAL CHANGES: A KEY TO MARTERNAL AND CHILD HEALTH. European Journal of Biomedical. 2023;10(8):42-43. links/64c890bddb38b20d6dad2c5c/PREGNANCY-INDUCED-HAEMATOLOGICAL-CHANGES-A-KEY-TO-MARTERNAL-AND-CHILD-HEALTH.pdf.
26. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
27. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. Annals of Clinical and Laboratory Research. 2017;5(4):206. links/5ea97df145851592d6a8acf2/Iron-Status-of-Pregnant-and-Post-Partum-Women-with-Malaria-Parasitaemia-in-Aba-Abia-State-Nigeria.pdf.
28. Eze RI, Obeagu EI, Edet FN. Frequency of Rh Antigen C And c among pregnant women in Sub-Urban area in Eastern Nigeria. Madonna Uni J Med Health Sci. 2021;1(1):19-30.

Citation: Obeagu EI, Obeagu GU. Addressing Anemia and Hemorrhage in Pregnancy: Blood Transfusion Strategies for Improved Maternal Health. *Elite Journal of Haematology, 2024; 2(6):* 46-59

29. Obeagu EI, Ofodile AC, Okwuanaso CB. A review of urinary tract infections in pregnant women: Risks factors. J Pub Health Nutri. 2023; 6 (1). 2023; 137:26-35. links/63c3a9116fe15d6a571e8bba/A-review-of-urinary-tract-infections-in-pregnant-women-Risks-factors.pdf.
30. Obeagu EI, Obeagu GU, Musiimenta E. Post partum haemorrhage among pregnant women: Update on risks factors. Int. J. Curr. Res. Med. Sci. 2023;9(2): 14-17.DOI: 10.22192/ijcrms.2023.09.02.003
31. Obeagu EI, Obeagu GU, Ogunnaya FU. Deep vein thrombosis in pregnancy: A review of prevalence and risk factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8): 14-21.DOI: 10.22192/ijcrcps.2023.10.08.002
32. Pacheco LD, Saade GR, Costantine MM, Clark SL, Hankins GD. An update on the use of massive transfusion protocols in obstetrics. American journal of obstetrics and gynecology. 2016;214(3):340-344.
33. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of some haematological parameters in malaria infected pregnant women in Imo state Nigeria. Int. J. Curr. Res. Biol. Med. 2018;3(9): 1-4.DOI: 10.22192/ijcrbm.2018.03.09.001
34. Onyenweaku FC, Amah HC, Obeagu EI, Nwandikor UU, Onwuasoanya UF. Prevalence of asymptomatic bacteriuria and its antibiotic susceptibility pattern in pregnant women attending private ante natal clinics in Umuahia Metropolitan. Int J Curr Res Biol Med. 2017;2(2): 13-23.DOI: 10.22192/ijcrbm.2017.02.02.003
35. Okoroiwu IL, Chinedu-Madu JU, Obeagu EI, Vincent CC, Ochiabuto OM, Ibekwe AM, Amaechi CO, Agu CC, Anoh NV, Amadi NM. Evaluation of Iron Status, Haemoglobin and Protein Levels of Pregnant Women in Owerri Metropolis. Journal of Pharmaceutical Research International. 2021;33(27A):36-43.
36. Obeagu EI, Njar VE, Obeagu GU. Infertility: Prevalence and Consequences. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(7):43-50.
37. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Evaluation of levels of some inflammatory cytokines in preeclamptic women in owerri. Journal of Pharmaceutical Research International. 2021;33(42A):53-65.
38. Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, Gernsheimer T, Holcomb JB, Kaplan LJ, Katz LM, Peterson N. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. Jama. 2016;316(19):2025-2035.
39. Obeagu EI, Faduma MH, Uzoma G. Ectopic Pregnancy: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4): 40-4.DOI: 10.22192/ijcrcps.2023.10.04.004
40. Obeagu EI, Gamade SM, Obeagu GU. The roles of Neutrophils in pregnancy. Int. J. Curr. Res. Med. Sci. 2023;9(5): 31-35.DOI: 10.22192/ijcrms.2023.09.05.005
41. Eze R, Obeagu EI, Nwakulite A, Okoroiwu IL, Vincent CC, Okafor CJ, Chukwurah EF, Chijioke UO, Amaechi CO. Evaluation of Copper Status and Some Red Cell Parameters of Pregnant Women in Enugu State, South Eastern Nigeria. Journal of Pharmaceutical Research International. 2021;33(30A):67-71.

Citation: Obeagu EI, Obeagu GU. Addressing Anemia and Hemorrhage in Pregnancy: Blood Transfusion Strategies for Improved Maternal Health. *Elite Journal of Haematology, 2024; 2(6):* 46-59

42. Obeagu EI, Obeagu GU. Molar Pregnancy: Update of prevalence and risk factors. Int. J. Curr. Res. Med. Sci. 2023;9(7): 25-28.DOI: 10.22192/ijcrms.2023.09.07.005
43. Obeagu EI, Bunu UO. Factors that influence unmet need for family planning. International Journal of Current Research in Biology and Medicine. 2023;8(1):23-27.
44. Ibebuike JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, Nwanjo HU, Agu GC, Ezenwuba CO, Nwagu SA, Akujuobi AU. Barriers to utilization of maternal health services in southern senatorial district of Cross Rivers state, Nigeria. International Journal of Advanced Multidisciplinary Research. 2017;4(8): 1-9.DOI: 10.22192/ijamr.2017.04.08.001
45. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
46. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of coagulation parameters in malaria infected pregnant women in Imo state, Nigeria. International Journal of Current Research in Medical Sciences. 2018;4(9): 41-9.DOI: 10.22192/ijcrms.2018.04.09.006
47. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8): 22-6.DOI: 10.22192/ijcrcps.2023.10.08.003
48. Obeagu E, Eze RI, Obeagu EI, Nnatuanya IN, Dara EC. ZINC LEVEL IN APPARENTLY PREGNANT WOMEN IN URBAN AREA. Madonna University journal of Medicine and Health Sciences. 2022;2(1):134-48. https://www.journal.madonnauniversity.edu.ng/index.php/medicine/article/view/40.
49. Rahman MM, Abe SK, Rahman MS, Kanda M, Narita S, Bilano V, Ota E, Gilmour S, Shibuya K. Maternal anemia and risk of adverse birth and health outcomes in low-and middle-income countries: systematic review and meta-analysis. The American journal of clinical nutrition. 2016;103(2):495-504.
50. Ogomaka IA, Obeagu EI. Malaria in Pregnancy Amidst Possession of Insecticide Treated Bed Nets (ITNs) in Orlu LGA of Imo State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(41B):380-386.
51. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. SICKLE CELL ANAEMIA: A GESTATIONAL ENIGMA. migration. 2023; 17:18.
52. Ifeanyi OE, Uzoma OG. A review on erythropietin in pregnancy. J. Gynecol. Womens Health. 2018;8(3):1-4. https://www.academia.edu/download/56538560/A_Review_on_Erythropietin_in_Pregnancy.pdf.
53. Ifeanyi OE. A review on pregnancy and haematology. Int. J. Curr. Res. Biol. Med. 2018;3(5): 26-8.DOI: 10.22192/ijcrbm.2018.03.05.006

Citation: Obeagu EI, Obeagu GU. Addressing Anemia and Hemorrhage in Pregnancy: Blood Transfusion Strategies for Improved Maternal Health. *Elite Journal of Haematology, 2024; 2(6):* 46-59

54. Nwosu DC, Nwanjo HU, Obeagu EI, Ibebuike JE, Ezeama MC. Ihekireh. Changes in liver enzymes and lipid profile of pregnant women with malaria in Owerri, Nigeria. International Journal of Current Research and Academic Review. 2015;3(5):376-383.
55. Ibebuike JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, Nwanjo HU, Agu GC, Ezenwuba CO, Nwagu SA, Akujuobi AU. Factors that influence women's utilization of primary health care services in Calabar Cros river state, Nigeria. Int. J. Curr. Res. Chem. Pharm. Sci. 2017;4(7):28-33.
56. Eze R, Ezeah GA, Obeagu EI, Omeje C, Nwakulite A. Evaluation of iron status and some haematological parameters of pregnant women in Enugu, South Eastern Nigeria. World Journal of Pharmaceutical and Medical Research. 2021;7(5):251-4.
57. Elemchukwu Q, Obeagu EI, Ochei KC. Prevalence of Anaemia among Pregnant Women in Braithwaite Memorial Specialist Hospital (BMSH) Port Harcourt. IOSR Journal of Pharmacy and Biological Sciences. 2014;9(5):59-64.
58. Akandinda M, Obeagu EI, Katonera MT. Non Governmental Organizations and Women's Health Empowerment in Uganda: A Review. Asian Research Journal of Gynaecology and Obstetrics. 2022;8(3):12-26.
59. Tandon R, Jain A, Malhotra P. Management of iron deficiency anemia in pregnancy in India. Indian Journal of Hematology and Blood Transfusion. 2018; 34:204-215.
60. Montoro M, Cucala M, Lanas Á, Villanueva C, Hervás AJ, Alcedo J, Gisbert JP, Aisa ÁP, Bujanda L, Calvet X, Mearin F. Indications and hemoglobin thresholds for red blood cell transfusion and iron replacement in adults with gastrointestinal bleeding: An algorithm proposed by gastroenterologists and patient blood management experts. Frontiers in Medicine. 2022; 9:903739.
61. Kapur D, Nath Agarwal K, Kumari Agarwal D. Nutritional anemia and its control. The Indian Journal of Pediatrics. 2002; 69:607-616.
62. Gamde MS, Obeagu EI. IRON DEFICIENCY ANAEMIA: ENEMICAL TO PREGNANCY. European Journal of Biomedical. 2023;10(9):272-275. links/64f63358827074313ffaae7b/IRON-DEFICIENCY-ANAEMIA-ENEMICAL-TO-PREGNANCY.pdf.
63. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Evaluation of levels of some inflammatory cytokines in preeclamptic women in owerri. Journal of Pharmaceutical Research International. 2021;33(42A):53-65.
64. Hasan MM, Magalhaes RJ, Garnett SP, Fatima Y, Tariqujjaman M, Pervin S, Ahmed S, Mamun AA. Anaemia in women of reproductive age in low-and middle-income countries: progress towards the 2025 global nutrition target. Bulletin of the World Health Organization. 2022;100(3):196.
65. Paulman PM, Paulman A, Harrison JD, Nasir LS, Bryan SK, Collier DS. Signs and Symptoms in Family Medicine E-Book: A Literature-Based Approach. Elsevier Health Sciences; 2011.

Citation: Obeagu EI, Obeagu GU. Addressing Anemia and Hemorrhage in Pregnancy: Blood Transfusion Strategies for Improved Maternal Health. *Elite Journal of Haematology, 2024; 2(6):* 46-59

66. Stoffel NU, von Siebenthal HK, Moretti D, Zimmermann MB. Oral iron supplementation in iron-deficient women: How much and how often? Molecular aspects of medicine. 2020; 75:100865.
67. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Studies of Some Haemostatic Variables in Preeclamptic Women in Owerri, Imo State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(42B):39-48.
68. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8):22-26.
69. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023;6(2):10-13.
70. Al RA, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, Haberal A. Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. Obstetrics & Gynecology. 2005;106(6):1335-1340.
71. Ngwenya S. Postpartum hemorrhage: incidence, risk factors, and outcomes in a low-resource setting. International journal of women's health. 2016:647-650.
72. Obeagu EI, Ubosi NI, Uzoma G. Maternal Hemorrhage and Blood Transfusions: Safeguarding Pregnancy Health. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):26-35.
73. Obeagu EI, Obeagu GU. The Vital Role of Blood Transfusions during Pregnancy: A Comprehensive Review. Asian Journal of Dental and Health Sciences. 2024;4(1):26-31.

Citation: Obeagu EI, Obeagu GU. Addressing Anemia and Hemorrhage in Pregnancy: Blood Transfusion Strategies for Improved Maternal Health. *Elite Journal of Haematology, 2024; 2(6):* 46-59